BDNF [19], NGF [18] and FGF2 [21] gene therapy did not have such effects on alleviating tau or APP/Aβ42 pathology in their respective pre- or post-symptomatic AD mouse models. This evidence concerns the gene MAPT and Alzheimer disease.